CPC 304
Latest Information Update: 17 Apr 2001
At a glance
- Originator Questcor Pharmaceuticals
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders; Stroke
Most Recent Events
- 17 Apr 2001 Discontinued-Preclinical for Neurological disorders in USA (Unknown route)
- 17 Apr 2001 Discontinued-Preclinical for Stroke in USA (Unknown route)
- 20 Dec 1999 Cypros Pharmaceutical has merged with RiboGene to form Questcor Pharmaceuticals